Alphabet stock continues its surge on the back of excitement around Google’s latest large-language model, while Tesla rises ...

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Just in time for the holiday season, Lilly unveiled its multi-pronged campaign to tie in Alzheimer’s awareness with cultural ...

An intimate bar and coffee area in the kitchen makes for a suitable backdrop for intimate gatherings, according to its listing. Spacious upper-level bedrooms have Jack-and-Jill baths. Other highlights ...

Seeking Alpha analysts have upgraded Nvidia (NVDA) and Alibaba (BABA), emphasizing their strategic positions in the AI and ...

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers ...

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...

Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or ...

Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants ...

Novo Nordisk A/S's Alzheimer's drug failed trials, impacting shares. Click here to read why NVO remains a value stock with ...